Pembrolizumab for advanced colorectal or lung cancer
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests pembrolizumab (an immune system medicine) with another treatment (TATE) in people with advanced colorectal or lung cancer that is not driven by certain gene changes. It may help shrink tumors after standard chemotherapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (metastatic) colorectal cancer with MSS, or advanced lung cancer
- Your tumor does not have EGFR or AKT mutations
- Your cancer has worsened after the required prior treatments (chemo alone for colorectal; chemo then an immune checkpoint drug for lung)
- You have measurable tumors on scans and can be assessed during the study
- Your body function tests are adequate, and you feel well enough (ECOG 0–1)
- At least 4 weeks have passed since your last chemotherapy, and you have recovered from side effects
- You do not have certain exclusions like prior organ transplant, brain (CNS) metastases, recent major bleeding, or an oxygen level under 92% while resting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This study tests a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) combined with two chemotherapy drugs, without radiation. It is for people with stage III lung cancer that has not spread and has a high PD-L1 level. The goal is to see if this treatment can shrink or control the cancer better than the usual approach.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy can help people with advanced non-small cell lung cancer that carries an EGFR exon 21 mutation and shows PD-L1 expression. The goal is to see if this combination helps shrink tumors or slow cancer growth more effectively.
Hear when a new Colorectal Cancer; Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.